Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian indices slip further in red
Mon, 30 Jan 01:30 pm

Indian stock markets indices lost further ground over the last two hours of trade on back of heavy selling activity witnessed across industry heavyweights. All the sectoral indices are trading in the red led by capital goods and power stocks.

The BSE-Sensex is down by 272 points, while the NSE-Nifty is down 87 points. Both BSE Mid cap index and the BSE Small cap index are down by 0.83% each. The rupee is trading at 49.48 to the US dollar.

Energy stocks are trading mixed with Essar Oil and Mangalore Refinery and Petrochemicals (MRPL) leading the gainers and Hindustan Petroleum Corporation Ltd (HPCL) and Bharat Petroleum Corporation Ltd. (BPCL) trading the weakest. Petronet LNG has announced its results for the third quarter of fiscal year 2012 (3QFY12). The company reported a topline growth of 74.5% on a year on year basis (YoY). The increase in revenues was driven by higher regasification volumes (up 21% YoY) and better margins. The operating profits for the quarter registered a growth of 45.6% YoY with margins at 7.9% (as compared to 9.5% in the 3QFY11). The margins improved on account of efficiency gains (company's Dahej terminal operated at 115% of the nameplate capacity during the quarter). The net profits for the quarter were up 72.9% with net profit margins at 4.7%, same as in the corresponding quarter last year. Besides, in a recent board meeting, the company has decided to set up its third terminal at Gangavaram port in Andhra Pradesh with an expected capacity of 5 million tonnes and at an estimated cost of Rs 45 bn. As per the management, the work on Kochi terminal is done to the extent of 94%-95% and operations are expected to commence by the month of October this year.

Pharma stocks are trading mixed with Sun Pharma and Dishman Pharma leading the gainers and Divi's Laboratories and Aurobindo Pharma trading the weakest. According to a leading financial daily, Ranbaxy Laboratories is up for a tough time ahead on account of regulatory issues. The company has been accused of making unsafe drugs for its crucial US market. As such, the company has to give up six months marketing exclusivity rights for three generic drugs where it has the first-to-file (FTF) status. The decree impacts its FTF cash flows from three drugs, with five more at risk. Besides, the company needs to hire an expert to review the plants that were found non compliant along with other procedures like withdrawal of applications based on false data which will mean additional costs and time that can delay the approval process.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian indices slip further in red". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.